This is an aggregated industry headline. Read the full story at Endpoints News →
Biogen filing reveals Apellis deal details; Telix raises $600M
Inside Biogen's $5.6B buyout: CEO Chris Viehbacher has carried on with diversifying Biogen's business beyond its legacy of high-risk bets in neurology. After paying $7.3 billion for Reata in 2023, Biogen
By Endpoints News
· Apr 15, 2026
· via Endpoints News
Image: Endpoints News
Tags
dealsformat:headlineheadlineEndpoints News
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Deals
All Deals →
DealsBriefing
The pharma giant’s latest acquisitions of Curevo, LimmaTech, and Vaccine Company reinforce its pivot from trea…
DealsFierceBiotech ↗
Medtronic has entered a deal to acquire SPR Therapeutics, a Cleveland-based company whose flagship product del…
DealsPharmaceutical Technology ↗
The tender offer is for €51.29 per share, representing a 13% premium on Recordati’s share price before the tak…